Mark Quick works as a Partner at Flerie AB having previously worked at Recipharm where he was Head of Corporate Development leading the M&A activities. Prior to that he held positions in ICI, Medeva, Celltech and UCB in various business development and supply chain roles. He is a board member of several of the Flerie portfolio companies both in drug development and commercial growth sectors. He has a first degree in Industrial Studies from Nottingham Trent University and an MBA from the Open Business School.

Erik Haeffler is the CEO of APL (Apotek Produktion & Laboratorier AB) – one of Europe's largest manufacturers of extemporaneous medicines and a leading contract manufacturer within the life science sector – and was previously Vice President Manufacturing Services & Head of Sustainability at Recipharm. Before that, Erik Haeffler held various positions within Supply Chain and Production, at AstraZeneca and Meda. Erik Haeffler holds a bachelor's degree in chemistry and microbiology from Stockholm University.

The nomination committee also proposes the re-election of Gisela Sitbon, Thomas Eldered, Mattias Bengtsson, Lena Torlegård and Jeremie Trochu. The current board member Anders Rabbe has declined re-election. Furthermore, Thomas Eldered is proposed as new chairman of the board.

Ahead of the 2026 Annual General Meeting, Nanologica's nomination committee consists of representatives of the company's three largest shareholders, who together represent 53 percent of the voting rights in the company. The nomination committee consists of:

• Carl-Johan Spak (Flerie Invest AB) – Chairman of the nomination committee
• Niklas Sjöblom (Konstakademiens stiftelser)
• Kalle Olby (Vega Bianca AB)

Nanologica's Annual General Meeting will be held on Thursday, May 21, 2026 at 10:00 a.m., at Advokatfirman Lindahl's premises at Smålandsgatan 16, Stockholm. The notice and documents for the Annual General Meeting, including the nomination committee's reasoned statement, will be published no later than Thursday, April 30, 2026.